ALGS Aligos Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALGS

Price (delayed)

$0.829

Market cap

$62.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.36

Enterprise value

-$61.91M

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver ...

Highlights
ALGS's quick ratio has surged by 81% since the previous quarter and by 49% year-on-year
Aligos Therapeutics's EPS has increased by 40% YoY and by 28% from the previous quarter
Aligos Therapeutics's equity has surged by 68% QoQ but it has decreased by 11% YoY
ALGS's revenue is up by 12% year-on-year but it is down by 5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aligos.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ALGS
Market
Shares outstanding
75.67M
Market cap
$62.73M
Enterprise value
-$61.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.67
Price to sales (P/S)
3.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.99
Earnings
Revenue
$15.53M
EBIT
-$88.13M
EBITDA
-$85.06M
Free cash flow
-$79.02M
Per share
EPS
-$1.36
Free cash flow per share
-$1.23
Book value per share
$1.23
Revenue per share
$0.24
TBVPS
$2.36
Balance sheet
Total assets
$151.53M
Total liabilities
$59.45M
Debt
$11.14M
Equity
$92.08M
Working capital
$117.18M
Liquidity
Debt to equity
0.12
Current ratio
5.9
Quick ratio
5.68
Net debt/EBITDA
1.47
Margins
EBITDA margin
-547.7%
Gross margin
100%
Net margin
-564.6%
Operating margin
-567.5%
Efficiency
Return on assets
-75.4%
Return on equity
-116.4%
Return on invested capital
-1,017.5%
Return on capital employed
-69.1%
Return on sales
-567.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALGS stock price

How has the Aligos Therapeutics stock price performed over time
Intraday
1.1%
1 week
4.94%
1 month
-16.26%
1 year
-17.51%
YTD
24.85%
QTD
-15.41%

Financial performance

How have Aligos Therapeutics's revenue and profit performed over time
Revenue
$15.53M
Gross profit
$15.53M
Operating income
-$88.13M
Net income
-$87.68M
Gross margin
100%
Net margin
-564.6%
The operating margin is up by 19% year-on-year but it has declined by 10% since the previous quarter
The company's net margin rose by 18% YoY but it fell by 13% QoQ
ALGS's revenue is up by 12% year-on-year but it is down by 5% since the previous quarter
ALGS's gross profit is up by 12% year-on-year but it is down by 5% since the previous quarter

Growth

What is Aligos Therapeutics's growth rate over time

Valuation

What is Aligos Therapeutics stock price valuation
P/E
N/A
P/B
0.67
P/S
3.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.99
Aligos Therapeutics's EPS has increased by 40% YoY and by 28% from the previous quarter
Aligos Therapeutics's equity has surged by 68% QoQ but it has decreased by 11% YoY
The stock's price to book (P/B) is 34% more than its last 4 quarters average of 0.5
The stock's price to sales (P/S) is 37% more than its last 4 quarters average of 2.5
ALGS's revenue is up by 12% year-on-year but it is down by 5% since the previous quarter

Efficiency

How efficient is Aligos Therapeutics business performance
The company's return on invested capital has shrunk by 129% QoQ
The return on equity has dropped by 56% year-on-year and by 12% since the previous quarter
ALGS's return on assets is down by 38% year-on-year and by 6% since the previous quarter
Aligos Therapeutics's ROS has increased by 19% YoY but it has decreased by 10% from the previous quarter

Dividends

What is ALGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALGS.

Financial health

How did Aligos Therapeutics financials performed over time
The total assets is 155% more than the total liabilities
The total liabilities has surged by 92% since the previous quarter and by 39% year-on-year
ALGS's quick ratio has surged by 81% since the previous quarter and by 49% year-on-year
The company's debt is 88% lower than its equity
Aligos Therapeutics's equity has surged by 68% QoQ but it has decreased by 11% YoY
ALGS's debt to equity is down by 43% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.